Media stories about Co-Diagnostics (NASDAQ:CODX) have been trending positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Co-Diagnostics earned a news impact score of 0.35 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 44.5648709058773 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Co-Diagnostics (NASDAQ CODX) traded up $0.01 during trading on Tuesday, reaching $2.79. 20,600 shares of the company were exchanged, compared to its average volume of 34,460. Co-Diagnostics has a one year low of $2.35 and a one year high of $6.85. The stock has a market capitalization of $33.53 and a P/E ratio of -5.17.
Co-Diagnostics, Inc is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.